I recently wrote an article titled Autonomous Imaging and it sparked a deeper reflection on the juxtaposition of the world in which I operate every day.

On one hand, I work in a MedTech company tasked with co-creating the future of medicine along with physicians. We challenge customers daily to rethink how technology will shape the next era of care. We ask them to trust a future where autonomous systems help address two undeniable facts: growing patient demand and a shrinking supply of trained clinicians.

We advocate a new belief: that patients will want to self-serve portions of their care because it’s more convenient, less friction-filled, and aligned with how they live their lives.

And many believe us.

The Commercial Double Standard

Yet, on the other hand, I operate inside a commercially driven organization that remains firmly anchored in today.

Here, we face a Commercial Double Standard.

While we champion autonomous technology to scale clinical delivery, we cling to the belief that sales success still requires more people, more calls, and more activity. Despite mounting evidence to the contrary, the belief persists.

We trust algorithms to assist in diagnosis. Yet we refuse to trust algorithms to identify a qualified lead.

That contradiction should make us uncomfortable.

The New Physics of B2B

The reality is simple: the physics of B2B has changed.

Buyers are no longer waiting for us to educate them; they are aggressively educating themselves. The math no longer supports a "more bodies" strategy.

Consider the modern buying environment:

• 70% of the B2B decision-making journey is complete before a buyer ever agrees to speak with a sales representative.
• 11 to 15+ stakeholders now sit on enterprise buying.
• 75% of buyers prefer a "sales rep-free" experience, viewing the discovery calls as friction.
• 5% is the maximum face-time a seller gets when competing against multiple vendors.

And yet, our commercial strategies often ignore these truths.

The Quagmire

This is the tension I confront daily.

We obsess over headcount, yet nearly 60% of buyers regret their purchase within 18 months. That’s not a closing problem—it’s a partnership problem.

We are winning deals while failing outcomes.

We are allocating resources to the wrong friction points and mistaking activity for effectiveness.

Reshaping Beliefs at the N of 1

Just as we leverage autonomous technology to meet patient demand and extend limited clinical supply, we must apply the same thinking to our commercial teams.

Autonomous workflows can:

• Identify buyers actively raising their hand.
• Reduce unnecessary friction in the buying journey.
• Direct sales teams toward moments where human engagement actually matters.

This isn’t about removing humans. It’s about using technology to amplify human impact, not waste it.

I’ve been far more successful reshaping clinical belief systems than commercial ones. Which leads me to the question I continue to wrestle with:

Why do we trust technology to help care for humans, but not to manage our sales pipeline?  

It’s a contradiction I intend to keep challenging—

one belief at a time,

at the N of 1.

Get insights like this delivered monthly.

Subscribe to the CancerGeek newsletter for exclusive perspectives on healthcare innovation, digital health trends, and more delivered straight to your inbox.